Bayer-action nahe Nulllinie: Bayer works in oncology with NextRNA sisters | 28.08.24

The pharmaceutical industry of Bayer and the American biotechnology NextRNA Therapeutics have made a strategic analysis of the development of active substances in the oncology industry.

Bayer and NextRNA were combined with an oncology program in the indication with an uncovered program, with the help of an outside company. NextRNA would generate an amount of 547 million US dollars for the two programs, one of the best from the Voraus- and Meilensteinzahlungen, the Forschungsförderung that is tiered on the Nettoumsatz.

The biotechnologists with Sitz in Boston have followed the development of innovative medicine with their specialized treatment of Krankheiten, while for a long time no RNAs (lncRNAs) were sold, with Schwerpunkt on oncology and neurological issues. When lncRNAs treat a therapeutic class, the RNA-binding proteins (RBPs) are recruited, a pathological process with different disease of strength. The interaction between lncRNAs and RBPs by small molecular components represents an innovative approach for the new therapeutic therapy.

De Rahmen der Kooperations- und Lizenzvereinbarung-zwischen de Unternehmen erhält Bayer Zugang zu NextRNAs differentiation Ansatz zur Hemmung der Funktion of lncRNAs durch Unterbrechung der Interaktion zwischen lncRNAs and RBPs with small Molecules. The common treatment of new medical therapies is a new class of diseases in oncology that strengthens Bayer’s pulmonary portfolio in the healthcare treatment center.

The Bayer promotion loses via XETRA a very marginal 0.02 Prozent auf 27.54 Euro.

FRANKFURT (Dow Jones)